Suzanne Cannegieter

Suzanne C. Cannegieter is a Dutch epidemiologist and clinician specializing in the etiology, prevention and treatment of venous thrombosis, renal venous thrombosis and hemostasis.[1][2] She holds a PhD in medicine from Leiden University and an MSc from the London School of Hygiene and Tropical Medicine. She is a clinical epidemiologist in the Departments of Clinical Epidemiology and Internal Medicine, Thrombosis and Hemostasis section of the Leiden University Medical Centre. In 2016 she was appointed Professor of Clinical Epidemiology and holds a visiting professor appointment at the Universidade de Minas Gerais in Belo Horizonte in Brazil.

Research Awards

Cannegieter works in leadership roles on several Dutch national multicenter research studies.[3][4] She is one of the principal investigators of a €3 million research grant awarded by the Dutch funding agency ZonMw to use predictive modelling to determine individual thrombosis risk and develop personalised treatment. Findings have been incorporated in clinical risk assessment in hospitals in the Netherlands, France and the UK.[5][6][7]

Achievements

In 2023 Cannegieter became the first woman co-Editor-in-Chief of the Journal of Thrombosis and Hemostasis (JTH).[8] She is also Associate Editor of Research and Practice in Thrombosis and Haemostasis[9] and Editorial Board Member for the Section Clinical Medicine of the journal PLOS Medicine.[10] She worked as a Scientific Advisory Committee member of the Dutch Thrombosis Foundation[11] and a board member for the Dutch charity Stichting De Merel, which supports healthcare research with a focus in medicine, recovery and rehabilitation.[12]

References

  1. ↑ "Suzanne Cannegieter". Leiden University. Retrieved 2026-03-06.
  2. ↑ "Suzanne Cannegieter : ECTH2025". www.ecth.org. Retrieved 2026-03-06.
  3. ↑ "Prof. dr S.C. (Suzanne) Cannegieter | LUMC". www.lumc.nl (in Dutch). Retrieved 2026-03-06.
  4. ↑ "1,3 miljoen euro voor onderzoek naar COVID-19 en trombose | LUMC". www.lumc.nl (in Dutch). Retrieved 2026-03-06.
  5. ↑ "Ruim 3 miljoen ZonMw-subsidie voor onderzoek naar persoonlijke antistollingbehandeling | LUMC". www.lumc.nl (in Dutch). Retrieved 2026-03-06.
  6. ↑ Lingsma, Tjitske (25 July 2023). "'Antistolling bij onderbeengips is niet altijd nodig' - Interview met Suzanne Cannegieter". ZonMw (Dutch Organisation for knowledge and innovation in health, healthcare and well-being). Retrieved 6 March 2026.{{cite web}}: CS1 maint: url-status (link)
  7. ↑ van Bijsterveldt, Marc (24 September 2025). "Risicomodel antistolling is inmiddels breed geïmplementeerd: Interview met Suzanne Cannegieter en Banne Németh". Dutch Organisation for knowledge and innovation in health, healthcare and well-being (ZonMw). Retrieved 6 March 2026.{{cite web}}: CS1 maint: url-status (link)
  8. ↑ "ISTH Announces new Editors for its Flagship Publication, the Journal of Thrombosis and Haemostasis - International Society on Thrombosis and Haemostasis, Inc". www.isth.org. Archived from the original on 2024-04-18. Retrieved 2026-03-06.
  9. ↑ "ISTH Announces new Editors for its Flagship Publication, the Journal of Thrombosis and Haemostasis - International Society on Thrombosis and Haemostasis, Inc". www.isth.org. Archived from the original on 2024-04-18. Retrieved 2026-03-06.
  10. ↑ "Editorial Board | PLOS Medicine". journals.plos.org. Retrieved 2026-03-06.
  11. ↑ "Suzanne Cannegieter". Leiden University. Retrieved 2026-03-06.
  12. ↑ "Stichting de Merel". CS Anbiportaal (in Dutch). Retrieved 2026-03-06.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.